We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$402M +$46.1M +1,080,486 +12%
BlackRock
2
BlackRock
New York
$230M +$15.7M +367,614 +7%
Sands Capital Management
3
Sands Capital Management
Virginia
$220M +$63.8M +1,495,303 +39%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$187M +$19.6M +458,192 +11%
RI
5
RTW Investments
New York
$134M -$163M -3,827,188 -54%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$123M -$24.6M -576,915 -16%
State Street
7
State Street
Massachusetts
$111M -$6.58M -154,149 -5%
ClearBridge Investments
8
ClearBridge Investments
New York
$96.7M -$2.01M -47,050 -2%
Alkeon Capital Management
9
Alkeon Capital Management
New York
$92.1M – – –
Federated Hermes
10
Federated Hermes
Pennsylvania
$86.6M +$7.19M +168,345 +9%
SCM
11
Suvretta Capital Management
New York
$84.7M +$16.4M +384,615 +23%
RSCM
12
Rock Springs Capital Management
Maryland
$79.1M +$6.37M +149,134 +8%
Millennium Management
13
Millennium Management
New York
$76.1M +$48.8M +1,142,829 +161%
VPC
14
Vestal Point Capital
New York
$74M +$72.2M +1,690,000 +1,536%
Deutsche Bank
15
Deutsche Bank
Germany
$73.3M +$24.6M +575,115 +48%
AllianceBernstein
16
AllianceBernstein
Tennessee
$62.8M +$1.94M +45,404 +3%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$61.9M +$7.07M +165,632 +12%
BBA
18
Baker Bros. Advisors
New York
$60.3M – – –
Invesco
19
Invesco
Georgia
$52.1M +$32.7M +765,466 +152%
Marshall Wace
20
Marshall Wace
United Kingdom
$46.6M +$7.01M +164,110 +17%
Adage Capital Partners
21
Adage Capital Partners
Massachusetts
$46.2M +$41.6M +975,000 +650%
Norges Bank
22
Norges Bank
Norway
$41.2M +$8.71M +203,959 +26%
FLAM
23
First Light Asset Management
Minnesota
$39.6M +$7.37M +172,700 +22%
APM
24
Avidity Partners Management
Texas
$39.5M +$1.13M +26,500 +3%
BNP Paribas Asset Management
25
BNP Paribas Asset Management
France
$34.1M +$13.8M +323,280 +64%
1
2 3 4 5

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.